GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile
Radium 223 Dichloride Reduces Death Risk By 30 Percent in Castration-Resistant Disease
Survey Finds 70 Percent of Oncologists Prescribe Avastin Off-Label For Ovarian Cancer
CMX001 Reduces Adenovirus Progression and Viremia
Biomarker Identified Predicting Graft-Versus-Host Disease Risk
Follow-up Finds Finasteride Reduces Prostate Cancer Risk Without Affecting Lifespan
Study Shows Early Treatment Of Asymptomatic Myeloma Can Improve Survival
Pretreatment with Azacitidine Achieves 28-Month Remission
Specific Pathology Pattern Can Predict Recurrence
20% of Women Do Not Believe Tailored Risk Assessments
Circulating Tumor Cells Predict Treatment Resistance In Study Of Metastatic Breast Cancer
Study Finds Gene Expression Test Predicts Stage I or II Recurrence
NCI CTEP Approved Trials For the Month of August
FDA Grants Orphan Designation To E7777 in T-Cell Lymphoma
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
